Rx-to-OTC Switch Pipelines USA: Competitive Assessment
|出版商||Kline & Company, Inc.||商品編碼||353967|
|出版日期||內容資訊||英文 433 Pages
|美國的處方藥改列成藥醫藥品的開發平台:競爭分析 Rx-to-OTC Switch Pipelines USA: Competitive Assessment|
|出版日期: 2015年05月31日||內容資訊: 英文 433 Pages||
Regional Coverage: United States
This report provides subscribers with a comprehensive, objective assessment of Rx-to-OTC switch pipelines by company in the United States. This analysis includes assessments of prescription-only pharmaceutical companies, as well as pharmaceutical companies with both OTC and prescription units. The report provides details on recently approved switches and forecasts of future switches by company. Included in the forecasts will be future switches in existing OTC categories and projected switches that would create new OTC categories.
This report helps subscribers to:
Rx-to-OTC Switch Pipelines USA: Competitive Assessment is the 11th edition in Kline's long running series of reports on Rx-to-OTC switch and seeks to examine future switch pipelines of OTC and prescription pharmaceutical companies. This report examines recent and future Rx-to-OTC switches by company in the United States. Each company's switch pipeline will be analyzed on a case-by-case basis, and the forecast time horizon may differ for each.
For each company and drug class, this report will provide:
Rx-to-OTC Switch Pipelines USA: Competitive Assessment is an extensive industry resource used by sales, marketing, and business development executives in the pharmaceutical industry for competitive analysis, market investigation, acquisition screening, business planning, and strategic purposes. The report provides a comprehensive, objective assessment of Rx-to- OTC switch pipelines by company in the United States, examines key issues and implications that switches can have on the existing OTC market, and identifies opportunities for future growth from switches. Accurately predicting Rx-to-OTC switches and assessing their competitive impact is crucial for maximizing business opportunities, minimizing threats, and successfully constructing long term strategic plans. Specifically, the report provides subscribers with the following key deliverables:
An executive briefing including the assessment of:
Assessment of companies shown in Table 1 including assessments of future switches in existing OTC categories and those that may create new OTC categories, including overview of the condition, comparative analysis of prescription and OTC markets (where applicable), regulatory issues including patent expiration data, safety/ efficacy, potential nonprescription indications and claims, likelihood of switch and expected timing, sales forecasts, expected competitive response from both branded and private-label products. Categories with potential switch candidates are shown in Table 2.